PCP [BTG]

Name: PCP [BTG]
SKU: DAG3016
Rating: 5 (1 reviews)

PCP, BTG-conjugated, synthetic

COA

SDS

Datasheet

Summary

Product Overview

Phencyclidine, BTG-Conjugated

Target

Phencyclidine

Nature

Synthetic

Tag/Conjugate

BTG

Format

Liquid

Concentration

5.0 mg/mL

Buffer

Supplied in 20 mM potassium phosphate, pH 7.5

Preservative

0.1% Sodium Azide

Storage

2-8°C short term, -20°C long term

Introduction

Phencyclidine, alsoknown as angel dust and myriad other street names, is a recreational,dissociative drug formerly used as an anesthetic agent, exhibitinghallucinogenic and neurotoxic effects. Developed in Germany in 1926, it wasfirst patented in 1952 by the Parke-Davis pharmaceutical company and marketedunder the brand name Sernyl. In chemical structure, PCP is anarylcyclohexylamine derivative, and, in pharmacology, it is a member of thefamily of dissociative anesthetics. PCP works primarily as an NMDA receptorantagonist, which blocks the activity of the NMDA receptor and, like mostantiglutamatergic hallucinogens, is significantly more dangerous than othercategories of hallucinogens. Other NMDA receptor antagonists includeketamine, tiletamine, dextromethorphan and nitrous oxide. Although theprimary psychoactive effects of the drug lasts for a few hours, the totalelimination rate from the body typically extends eight days or longer.As arecreational drug, PCP may be ingested, smoked, or snorted. Phencyclidine modulates secretogranin II[sg II] expression inprefrontal cortex tissue in the absence of afferent inputs. The nature ofthese changes is dependent upon the duration of exposure to and/or withdrawalfrom phencyclidine. It is used as an anesthetic by veterinarians and isillicitly taken for its hallucinogen effects.

Keywords

PCP; Phenylcyclohexylpiperidine; PHENCYCLIDINE; Phencylidine; OTTHUMP00000109191; PEP19; Purkinje cell protein 4; Phencyclidine solution

Citations

Have you cited DAG3016 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study

BJPSYCH OPEN

Authors: Bodnar, Michael; Malla, Ashok K.; Makowski, Carolina; Chakravarty, M. Mallar; Joober, Ridha; Lepage, Martin

Abstract

Background Current neuroscience literature has related treatment with aripiprazole to improved memory performance and subcellular changes in the hippocampus. Aims To explore the volumetric changes in hippocampal grey matter in people with a first episode of psychosis (FEP) treated with second-generation antipsychotics. Method Baseline and 1-year follow-up magnetic resonance images were obtained. Hippocampal volumes were estimated by using FreeSurfer and MAGeT-Brain. Subgroups included: aripiprazole (n= 13), olanzapine (n= 12), risperidone/paliperidone (n= 24), refused-antipsychotics (n= 13) and controls (n= 44). Results Aripiprazole subgroup displayed significant increases in bilateral hippocampal volume compared with all other subgroups (FreeSurfer: all P's< 0.012; MAGeT-Brain: all P's< 0.040). Conclusions Aripiprazole is a first-line, second-generation treatment option that may provide an added benefit of pro-hippocampal growth. The biological underpinnings of these changes should be the focus of future investigations and may be key towards achieving a better clinical outcome for more individuals. Copyright and usage (C) The Royal College of Psychiatrists 2016.

Differential control of dopamine ascending pathways by serotonin(2B) receptor antagonists: New opportunities for the treatment of schizophrenia

NEUROPHARMACOLOGY

Authors: Devroye, Celine; Cathala, Adeline; Haddjeri, Nasser; Rovera, Renaud; Vallee, Monique; Drago, Filippo; Piazza, Pier Vincenzo; Spampinato, Umberto

Abstract

Recent studies suggest that the central serotonin(2B) receptor (5-HT2BR) could be an interesting pharmacological target for treating neuropsychiatric disorders related to dopamine (DA) dysfunction, such as schizophrenia. Thus, the present study was aimed at characterizing the role of 5-HT(2B)Rs in the control of ascending DA pathway activity. Using neurochemical, electrophysiological and behavioral approaches, we assessed the effects of two selective 5-HT2BR antagonists, RS 127445 and LY 266097, on in vivo DA outflow in DA-innervated regions, on mesencephalic DA neuronal firing, as well as in behavioral tests predictive of antipsychotic efficacy and tolerability, such as phencyclidine (PCP)-induced deficit in novel object recognition (NOR) test, PCP -induced hyperlocomotion and catalepsy. Both RS 127445 (0.16 mg/kg, i.p.) and LY 266097 (0.63 mg/kg, i.p.) increased DA outflow in the medial prefrontal cortex (mPFC). RS 127445, devoid of effect in the striatum, decreased DA outflow in the nucleus accumbens, and potentiated haloperidol (0.1 mg/kg, s.c.)-induced increase in mPFC DA outflow. Also, RS 127445 decreased the firing rate of DA neurons in the ventral tegmental area, but had no effect in the substantia nigra pars compacta. Finally, both RS 127445 and LY 266097 reversed PCP -induced deficit in NOR test, and reduced PCP -induced hyperlocomotion, without inducing catalepsy. These results demonstrate that 5-HT(2B)Rs exert a differential control on DA pathway activity, and suggest that 5-HT2BR antagonists could represent a new class of drugs for improved treatment of schizophrenia, with an ideal profile of effects expected to alleviate cognitive and positive symptoms, without eliciting extrapyramidal symptoms. (C) 2016 Elsevier Ltd. All rights reserved.